Relative Bioavailability, Safety, and Tolerability Following Subcutaneous Injection of Different Doses of BI 655130 and Different Injection Sites in Healthy Male and Female Subjects (a Single Dose, Mono-centric, Open-label Study in Matched-group Design)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Spesolimab (Primary)
- Indications Crohn's disease; Palmoplantar pustulosis; Pustular psoriasis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 29 Oct 2018 Planned End Date changed from 27 May 2019 to 20 May 2019.
- 29 Oct 2018 Planned primary completion date changed from 27 May 2019 to 20 May 2019.